Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Clin Genitourin Cancer. 2019 May 2;17(4):268–274.e1. doi: 10.1016/j.clgc.2019.04.006

Figure 1. Overall survival of patients with MTSCC from first pathological diagnosis.

Figure 1.

3-year overall survival from first pathological diagnosis with MTSCC was 84.8% (95% CI: 59.6, 94.9) for all patients with a median follow-up time for survivors of 3.9 years (range: 1 months, 10.3 years). Three deaths occurred which were all from metastatic disease at 3.7, 15.0 and 29.2 months.